US · Healthcare · Biotechnology
EPS came in at -0.63 against a street estimate of -0.67 — a beat of 6.0%.
Analysts rate Kyverna Therapeutics, Inc. Common Stock a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $30.40.
| Fund | Stake |
|---|---|
| GordonMD Global Investments LP | 6.86% |
| BlackRock Inc | 5.07% |
| Bain Capital Life Sciences Investors, LLC | 4.67% |
| AIGH Capital Management, LLC | 4.52% |
| Deerfield Management Co | 3.23% |
| Vanguard Capital Management, LLC | 3.07% |
| T. Rowe Price Associates, Inc. | 1.92% |
| Geode Capital Management, LLC | 1.70% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kyverna Therapeutics, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.